Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Mitral regurgitation Stories

2011-11-07 17:32:00

KIRKLAND, Wash., Nov. 7, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that an update to its landmark TITAN clinical trial will be given as part of the 23rd annual Transcathether Cardiovascular Therapeutics (TCT) Conference being held at the Moscone Center in San Francisco. Steven L. Goldberg, M.D., the Company's Chief Clinical Officer will deliver a presentation entitled, Cardiac Dimensions CARILLON XE2: Foundational Results and Design Iteration Toward...

2011-10-13 05:00:00

KIRKLAND, Wash., Oct. 13, 2011 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced that it had named sales and marketing executive Omari V. Bouknight its Vice President of Sales and Marketing, effective Oct. 12. He reports directly to President and Chief Executive Officer Rick Stewart. Bouknight has primary responsibility for the commercialization of the CARILLON(®) Mitral Contour System((TM)) throughout Europe. The CARILLON system, which...

2011-10-11 05:00:00

KIRKLAND, Wash., Oct. 11, 2011 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced the first patient has been enrolled and successfully treated in the TITAN II clinical trial, a follow-up to the landmark TITAN clinical trial of the Company's CARILLON(®) Mitral Contour System((TM)). TITAN II is a prospective, single-arm clinical trial initiated to further evaluate an enhanced version of the CARILLON system, a novel therapy for treating heart...

2011-09-29 16:47:00

KIRKLAND, Wash., Sept. 29, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that it has received Conformite Europeenne (CE) Mark approval for a newly enhanced version of its CARILLON® Mitral Contour System(TM), a novel therapy for treating heart failure patients suffering from functional mitral regurgitation (FMR). Receipt of the CE Mark enables Cardiac Dimensions to initiate a commercial launch of the enhanced device in Europe, which the...

75da28fbfb354e1abff3b9a5a0a2a68c
2011-08-09 09:28:50

A new study into the causes of leakage in one of the heart's most complex valve structures could lead to improved diagnosis and treatment of the condition. An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valve, a complex structure that closes off the heart's right ventricle from the right atrium. Most people have at least some leakage in the valve, but what causes the problem is not well understood. A new study, published online in the journal...

2011-07-21 06:32:00

--Proceeds Will be Used To Fund New Initiative to Treat Mitral Valve Disease and to Complete Neovasc Reducer(TM) COSIRA Trial for Treating Refractory Angina-- TSX Venture Exchange: NVC VANCOUVER, July 21, 2011 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that it intends to complete a non-brokered private placement with accredited investors of up to four million equity units at the price of $1.00 per unit for aggregate gross proceeds of up to $4.0 million. The company...

2011-07-20 09:30:00

STOUGHTON, Mass., July 20, 2011 /PRNewswire/ -- STD Med, Inc., a worldwide manufacturer and innovator of medical devices located in Stoughton, Massachusetts, is pleased to announce that one of its internally incubated medical device technologies, Spirus Medical, Inc., has been successfully acquired by Olympus Corporation. Spirus Medical, with its proprietary "rotate to advance technology" for diagnosis and treatment of gastrointestinal (GI) disorders, is the second exit for the medical...

2011-06-29 07:00:06

(Ivanhoe Newswire) "“ Individuals with diastolic dysfunction (impaired relaxation of the heart's ventricle after contraction) appear to have increased risk of death, regardless of whether their systolic function (contraction of the ventricle) is normal or they have other cardiovascular impairments, according to this study. During each heartbeat, the heart contracts (pumping blood out, a phase called systole) and then relaxes (allowing the heart chambers to refill with blood, a phase...

2011-06-24 23:06:56

 An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered at Rush University Medical Center to patients with severe aortic stenosis who are at high-risk or not suitable candidates for open heart valve replacement surgery. "This breakthrough technology could save the lives of thousands of patients with heart valve disease who have no other therapeutic options," says Dr. Ziyad Hijazi, director of the Rush Center for Congenital and...

2011-05-04 05:00:00

KIRKLAND, Wash., May 4, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. announced today the initiation of two new clinical studies using the CARILLON® Mitral Contour System(TM), an investigational device for percutaneous treatment of Functional Mitral Regurgitation (FMR). The CARILLON system is a minimally invasive device designed to repair the heart's mitral valve and reduce FMR, a disorder that affects most of the estimated 5 million people in the U.S....